← Back to Search

Anti-fibrinolytic agent

Tranexamic Acid Mist for Tonsillar Bleeding (TEAPOT Trial)

Phase < 1
Waitlist Available
Led By Andrew D Meyer, MD, MS
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Presents to the ED with secondary post-tonsillectomy hemorrhage
Received a tonsillectomy
Must not have
Known and documented bleeding or clotting disorder
Parents or guardians who cannot communicate in English or Spanish
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 18 months (or duration of study)

Summary

This trial is testing a special mist medicine called nebulized tranexamic acid (TXA) to see if it can help stop bleeding after tonsil removal in children. If successful, this mist

Who is the study for?
This trial is for children who have had their tonsils removed and are experiencing bleeding afterwards. It's important that they haven't had any reactions to tranexamic acid before, and they aren't currently taking medication that affects blood clotting.
What is being tested?
The study is testing a mist medicine called nebulized tranexamic acid (TXA) against normal saline to see if TXA can stop post-operative bleeding in kids without additional surgery or the need for blood transfusions.
What are the potential side effects?
Tranexamic acid may cause side effects like headaches, muscle cramps, or an upset stomach. In rare cases, it could cause more serious problems like blood clots or allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am experiencing bleeding after a tonsil removal surgery.
Select...
I have had my tonsils removed.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a known bleeding or clotting disorder.
Select...
My parents or guardians do not speak English or Spanish.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 18 months (or duration of study)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 18 months (or duration of study) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Indirect local concentration of nebulized TXA
Number of nebulizations per patient
Number of patients enrolled per month
+1 more
Secondary study objectives
Estimated blood loss
Number of blood transfusions required
Number of recurrences of PTH
+1 more
Other study objectives
State-Trait Anxiety Inventory (STAI) for Adults
State-Trait Anxiety Inventory for Children (STAIC)
Wong-Baker FACES Pain Rating Scale

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Nebulized Tranexamic AcidExperimental Treatment1 Intervention
Subjects will be adminstered nebulized TXA post-tonsillectomy if they return to the emergency room with hemorrhage after surgery
Group II: Nebulized SalinePlacebo Group1 Intervention
Subjects will be adminstered nebulized saline post-tonsillectomy if they return to the emergency room with hemorrhage after surgery
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tranexamic Acid Injectable Product
2020
Completed Phase 4
~430

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor
477 Previous Clinical Trials
92,958 Total Patients Enrolled
Andrew D Meyer, MD, MSPrincipal InvestigatorThe University of Texas Health Science Center at San Antonio
~8 spots leftby Sep 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top